Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
暂无分享,去创建一个
M. Ziepert | K. Stamatopoulos | R. Rosenquist | P. Zinzani | R. Amini | N. Goldschmidt | M. Bouzani | F. Asmar | G. Kanellis | T. Vassilakopoulos | V. Poeschel | A. Staiger | Y. Takeuchi | F. Briest | R. Hablesreiter | Daniel Noerenberg | C. Hennch | Hiroo Ueno | Csaba Bödör | Seishi Ogawa | G. Ott | Lars Bullinger | Gerhard Held | Frederik Damm | Kenichi Yoshida | Benjamin N Locher | Erika Toth | Thomas Weber | Wolfram Klapper | Andreas Rosenwald | Elías Campo | Naveed Ishaque | Ioannis Anagnostopoulos | Erika Tóth
[1] W. Klapper,et al. Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma , 2023, Leukemia.
[2] D. Schadendorf,et al. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. , 2023, Cancer cell.
[3] R. Houot,et al. Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study. , 2021, Blood advances.
[4] M. Dimopoulos,et al. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. , 2021, The oncologist.
[5] Ash A. Alizadeh,et al. CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering , 2020 .
[6] D. Scott,et al. Outcome of Primary Mediastinal Large B-cell Lymphoma Using R-CHOP: Impact of a PET Adapted Approach. , 2020, Blood.
[7] M. Piris,et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up , 2020, Blood Cancer Journal.
[8] Andrew J. Dunford,et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. , 2019, Blood advances.
[9] Andrew J. Dunford,et al. Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. , 2019, Blood.
[10] Lauren C. Chong,et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. , 2019, Blood.
[11] L. Bullinger,et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. , 2019, Blood.
[12] Chuang Tan,et al. Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.
[13] Alexander V Penson,et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. , 2018, Blood.
[14] F. Cavalli,et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. , 2018, Blood.
[15] Stefano Monti,et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.
[16] Angela E. Leek,et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.
[17] D. Dunson,et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.
[18] S. Miyano,et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.
[19] Jiachun Zheng,et al. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2 , 2017, Oncotarget.
[20] W. Wilson,et al. DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation , 2017, Front. Pediatr..
[21] A. Rosenwald,et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. , 2016, Blood.
[22] Satoru Miyano,et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.
[23] R. Advani,et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. , 2016, Blood.
[24] H. Aburatani,et al. Integrated molecular analysis of adult T cell leukemia/lymphoma , 2015, Nature Genetics.
[25] A. Valencia,et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.
[26] C. Chen,et al. Altered lymphopoiesis and immunodeficiency in miR-142 null mice. , 2015, Blood.
[27] O. Elemento,et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.
[28] R. Gascoyne,et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma , 2014, Nature Genetics.
[29] S. Miyano,et al. The landscape of somatic mutations in Down syndrome–related myeloid disorders , 2013, Nature Genetics.
[30] David I Heiman,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2013, Nature.
[31] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[32] H. Kume,et al. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data , 2013, Nucleic acids research.
[33] Govind Bhagat,et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.
[34] A. Ho,et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] K. Garcia,et al. Structural Basis of Semaphorin-Plexin Recognition and Viral Mimicry from Sema7A and A39R Complexes with PlexinC1 , 2010, Cell.
[36] B. Cheson. The International Harmonization Project for response criteria in lymphoma clinical trials. , 2007, Hematology/oncology clinics of North America.
[37] Dirk Hasenclever,et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.
[38] M. Paulli,et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B , 2004, British Journal of Cancer.
[39] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[40] L. Staudt,et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.
[41] G. Melino,et al. p73: Friend or foe in tumorigenesis , 2002, Nature Reviews Cancer.